key: cord-0688016-6cv0xav1
authors: Karyagina, Anna S.; Gromov, Alexander V.; Grunina, Tatyana M.; Lyaschuk, Alexander M.; Grishin, Alexander V.; Strukova, Natalia V.; Generalova, Maria S.; Galushkina, Zoya M.; Soboleva, Lyubov’ A.; Dobrinina, Olga Yu.; Bolshakova, Tatyana N.; Subbotina, Marina E.; Romanovskaya-Romanko, Ekaterina A.; Krasilnikov, Igor V.; Polyakov, Nikita B.; Solovyev, Andrey I.; Grumov, Daniil A.; Zhukhovitsky, Vladimir G.; Ryabova, Ekaterina I.; Prokofiev, Vladimir V.; Lunin, Vladimir G.
title: Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19
date: 2021-10-20
journal: Biochemistry (Mosc)
DOI: 10.1134/s0006297921100096
sha: f234fa8c9fa6da83ddbc52020fe7f9279883fa7b
doc_id: 688016
cord_uid: 6cv0xav1

A new platform for creating anti-coronavirus epitope vaccines has been developed. Two loop-like epitopes with lengths of 22 and 42 amino acid residues were selected from the receptor-binding motif of the Spike protein from the SARS‑CoV‑2 virus that participate in a large number of protein-protein interactions in the complexes with ACE2 and neutralizing antibodies. Two types of hybrid proteins, including one of the two selected epitopes, were constructed. To fix conformation of the selected epitopes, an approach using protein scaffolds was used. The homologue of Rop protein from the Escherichia coli ColE1 plasmid containing helix-turn-helix motif was used as an epitope scaffold for the convergence of C- and N-termini of the loop-like epitopes. Loop epitopes were inserted into the turn region. The conformation was additionally fixed by a disulfide bond formed between the cysteine residues present within the epitopes. For the purpose of multimerization, either aldolase from Thermotoga maritima, which forms a trimer in solution, or alpha-helical trimerizer of the Spike protein from SARS‑CoV‑2, was attached to the epitopes incorporated into the Rop-like protein. To enable purification on the heparin-containing sorbents, a short fragment from the heparin-binding hemagglutinin of Mycobacterium tuberculosis was inserted at the C-terminus of the hybrid proteins. All the obtained proteins demonstrated high level of immunogenicity after triplicate parenteral administration to mice. Sera from the mice immunized with both aldolase-based hybrid proteins and the Spike protein SARS‑CoV‑2 trimerizer-based protein with a longer epitope interacted with both the inactivated SARS‑CoV‑2 virus and the Spike protein receptor-binding domain at high titers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1134/S0006297921100096.

If COVID 19 becomes a seasonal disease, the world's population will need periodic vaccinations, just as it happens in the framework of influenza prevention, which makes development of new variants of highly effec tive, safe, and inexpensive vaccines for the prevention of COVID 19 an extremely urgent task. One of the prob BIOCHEMISTRY (Moscow) Vol. 86 No. 10 2021 lems of the whole virion vaccines (protein vaccines con taining full length viral proteins) and vector vaccines (RNA vaccines leading to the production of viral proteins in the body) is that not all antibodies they induce are pro tective [1] . Moreover, under certain circumstances, anti bodies can be formed that contribute to a more severe course of the disease upon infection after vaccination (the phenomenon of antibody dependent enhancement of infection) [2 4 ]. One of the promising approaches that allow to knowingly avoid several problems, including the ones listed above, is the development of the so called epi tope vaccines -vaccines based on the individual small protein epitopes of an infectious agent. They do not have the disadvantages typical of live vaccines (reversion of pathogenic properties, residual virulence, incomplete inactivation, etc.). In addition, such vaccines are highly standardized, have weak reactogenicity, and can be used to avoid both development of autoimmune processes during immunization and formation of the non protective anti bodies and antibodies that contribute to the development of antibody dependent enhancement of virus infection.

The basis for successful functioning of epitope vac cines is the correct selection of epitopes -surface regions of viral proteins that can effectively induce formation of the desired spectrum of antibodies. An adequate selec tion of epitopes can direct immune system to produce only virus neutralizing antibodies. In the case of the SARS CoV 2 virus, the choice of epitopes can be based directly on the structural data of complexes of the surface Spike protein, which is responsible for cell penetration, with the human virus neutralizing antibodies. Such opportunity is provided by the rapid accumulation of the necessary structural data: for example, in the spring and summer of 2020, the first data describing structure of the complexes were published [5] , and at the end of May 2021 200 structures of Spike protein complexes with antibodies have already been deposited in the Protein Data Bank database (PDB, https://www.rcsb.org/). Neutralizing antibodies that interact with Spike protein can be divided into several classes according to the region of interaction. A large class of neutralizing antibodies directly inhibit interaction of the Spike protein with angiotensin converting enzyme 2 (ACE2), which initi ates viral entry into the cell. These antibodies are in con tact with amino acid residues (aa) located in the so called receptor binding motif (RBM, 437 508 aa); therefore, it seems appropriate to choose determinants for epitope vaccines within this motif.

Another important aspect of the success of epitope vaccines is solving the problem of low immunogenicity by ensuring optimal exposure of epitopes and their multi merization. The most promising modern strategies in this area are associated with the use of approaches based on the so called epitope scaffolds. Epitope scaffolds are usu ally determined as carrier proteins to which peptide epi topes are attached by means of genetic engineering or others [6, 7] . Proteins forming trimeric, tetrameric, or hexameric structures are often used as carrier proteins. In this case, short linear determinants can induce produc tion of the protective antibodies when located at the N terminus of the scaffold protein apparently due to sponta neous formation of the native conformation [6] . Sufficiently extended linear epitopes of viral proteins, which form numerous contacts in complexes with anti bodies, can be represented in the structure of the viral protein by the loop like structures with N and C ends close to each other. In this case, the scaffold protein can be used for fixing the ends of the loop like protein regions close to each other, similarly to the work done by Juraja et al. [8] . It can be expected that the conforma tional correspondence of the epitope to its native confor mation in the composition of the full length antigen will be largely ensured with this approach.

The aim of this work was to develop a new platform for creating protein components of the epitope anticoro navirus vaccines based on either epitope scaffold for fix ing conformation, or on the domain for multimerization (trimerization) of epitopes. al residues representing linker sequences and residues corresponding to the nucleotide sequences with intro duced restriction sites. The sites NcoI and BamHI were inserted at the 5′ end of the nucleotide sequence, and BglII and Kpn2I at the 3′ end. The synthetic gene was inserted into a modified plasmid vector pQE6 carrying the T7 promoter instead of the T5 promoter at the NcoI and Kpn2I sites. As a result, the plasmid pL926 encoding the Rop RBM Rop protein was obtained.

In all cases, correct assembly of the sequences was confirmed by Sanger sequencing.

Cultivation of producer strains. Cultures of trans formed E. coli cells were grown in LB media supplement ed with kanamycin (25 mg/liter) and ampicillin (200 mg/liter) on a shaker at 180 rpm and 37°C until OD 600 reached 1.0 1.2. Protein synthesis was induced by addition of 0.5 mM IPTG (isopropyl β D thiogalac topyranoside), then the cultures were grown for another 4 h at 180 rpm. Producers of insoluble proteins were cul tured at 37°C, and of soluble ones -at 30°C. The result ing cell cultures were centrifuged for 30 min at 5,000g and 10°C. The biomass was stored at -20°C.

Disruption of E. coli cells. Thawed biomass of bacte rial cells (1 g) was suspended in a lysis buffer [20 mM Tris HCl (pH 8.0), 100 mM NaCl, 1% Triton X 100, 1 mM phenylmethylsulfonyl fluoride (PMSF)] at a ratio of not less than 1 : 10 (w/v), next 100 μg/ml of lysozyme was added, incubated for 20 min at room temperature, and cells were disrupted with a Vibra Cell VCX750 ultrasonic device (Sonics, USA) at 40% amplitude for 2. ple was centrifuged at 9,000g for 30 min producing the target protein mainly in the supernatant, and the contam inating bacterial proteins mainly in the sediment.

Column chromatography. Column chromatography was performed using a low pressure chromatographic unit ÄKTA start (GE Healthcare Life Sciences, USA). Protein concentration was determined by absorbance at 280 nm using the Bicinchoninic acid (BCA) Protein Assay (AppliChem, Germany). To prepare protein sam ples for polyacrylamide gel electrophoresis (PAGE) according to Laemmli, we used a buffer containing 2 mM EDTA, 125 mM Tris HCl (pH 6.8), 20% glycerol, 4% sodium dodecyl sulfate and 0.015% bromophenol blue supplemented with a reducing agent (0.2 M dithiothre itol, DTT) or without it. Protein samples were diluted with a buffer at a 1 : 1 ratio, heated for 5 min at 95°C, and centrifuged for 5 min at 16,000g; the supernatant was applied to PAGE. Electrophoresis was performed using an SE 260 Mighty Small II device (Amersham, USA) and a set of accessories from GE Healthcare. After elec trophoresis, the gels were stained with Coomassie brilliant blue R250 (Bio Rad, USA). To estimate apparent molec ular weights, set of 14 97 kDa protein markers (Bio Rad) was used. The gels were imaged using a Gel Doc™ XR + gel documentation system (Bio Rad). Densitometric evaluation of bands on the gel was performed using a Quantity One software (Bio Rad).

Chromatography of proteins from inclusion bodies on WorkBeads 40S sorbent. The proteins Rop D2 Rop Tri HBD, Rop D3 Rop Tri HBD, and Rop RBM Rop prepared for chromatography were loaded onto a column with 6 ml of WorkBeads 40S sorbent (Bio Works, Sweden) equilibrated with a solution of 8 M urea in 10 mM Tris HCl (pH 8.0), at a rate of 1 ml/min, column washed at a rate of 2 ml/min until the absorption at 280 nm reached a plateau. Elution was carried out at the same rate with a solution of NaCl (a linear concentration gradient of 0 1 M in a volume of 60 ml) in the same buffer. The eluate from the column was collected in 5 ml fractions, then the fractions of the eluate with maximum absorbance at 280 nm were combined and dialyzed against a solution of 4 M urea in 25 mM Tris HCl buffer (pH 8.0) for 24 h at 4°C and centrifuged in for 30 min at 9,000g. The volume ratio of the dialyzed sample to the dialysis buffer was 1 : 10. Protein solutions (hereinafter) were dialyzed using a Zellu Trans/ROTH 3,5 E657.1 cel lulose dialysis membrane (Carl Roth, Germany) with 25 μm thickness and molecular weight cut off 3500 Da. After dialysis, electrophoresis of the pooled fractions was performed, and protein concentration was estimated from the absorbance of the solution at 280 nm using the BCA Protein Assay.

Chromatography of soluble proteins on WorkBeads 40S sorbent. The proteins Rop D2 Rop ALD HBD and Rop D3 Rop ALD HBD prepared for chromatography were filtered with a syringe through a polyethersulfone (PES) membrane filter with a pore diameter of 0.45 μm (Corning, USA). The filtrate was applied to a column with 10 ml of WorkBeads 40S sorbent, equilibrated with 20 mM Tris HCl, pH 8.0 at a rate of 1 ml/min, washed at a rate of 2 ml/min until the absorption at 280 nm reached a plateau. The elution was carried out at the same rate with a solution of NaCl (with a linear concentration gra dient of 0 1 M in a volume of 100 ml) in the same buffer, the eluate from the column was collected in 4 ml frac tions, then the fractions corresponding to maximum absorption at 280 nm were combined and dialyzed against a buffer containing 20 mM Tris HCl (pH 8.0) for 24 h, centrifuged for 30 min at 9,000g. The volume ratio of the dialyzed sample to the dialysis buffer was 1 : 10. Then, the supernatant was taken, and electrophoresis of the obtained proteins was carried out and protein concentra tion was estimated by the absorbance of the solution at 280 nm using the BCA Protein Assay.

Affinity chromatography of Rop D2 Rop Tri HBD and Rop D3 Rop Tri HBD proteins on heparin sepharose CL 6B. The resulting protein solution after dialysis was subjected to affinity chromatography on heparin sepharose CL 6B column (GE Healthcare). The column with 10 ml of sorbent was equilibrated with a solution of 4 M urea in 20 mM Tris HCl buffer (pH 8.0), protein binding and column washing were carried out in the same buffer, all operations were performed at a flow rate of 1 ml/min. The protein was eluted with a 0 1 M NaCl concentration gradient in a 4 M urea solution in Tris HCl buffer (pH 8.0) at a flow rate of 1 ml/min. Protein fractions of a total volume of 3 ml were dialyzed against 25 mM Tris HCl buffer (pH 6.8), gradually decreasing the urea concentration in the dialysis buffer (0.5 M steps) for 24 h at 4°C. The ratio of the volume of the dialyzed sample to the dialysis buffer was 1 : 10 at all stages of dialysis. After dialysis, concentration and total amount of protein were determined based on absorbance of the solution at 280 nm using the BCA Protein Assay. The obtained protein preparations were lyophilized and used for further studies.

Affinity chromatography of soluble proteins on heparin sepharose CL 6B. The resulting solution of Rop D2 Rop ALD HBD and Rop D3 Rop ALD HBD proteins after dialysis was loaded onto columns with 10 ml of heparin sepharose sorbent equilibrated with 20 mM Tris HCl buffer (pH 8.0). Protein binding and column washing were performed in the same buffer; all operations were performed at a flow rate of 1 ml/min. The protein was eluted with a 0 1 M NaCl concentration gra dient in 20 mM Tris HCl buffer (pH 8.0) at a rate of 1 ml/min. Three 2 ml fractions were collected. Protein fractions with a total volume of 6 ml were pooled and dia lyzed against a 20 mM Tris HCl buffer (pH 8.0), 50 mM NaCl at a volume ratio of 1 : 10 for 24 h at 4°C with three buffer changes. After dialysis, concentration and total amount of protein were determined based on absorbance BIOCHEMISTRY (Moscow) Vol. 86 No. 10 2021 of the solution at 280 nm using the BCA Protein Assay. The obtained protein preparations were lyophilized and used for further studies.

Chromatography of Rop RBM Rop protein on WorkBeads 40 DEAE sorbent. A solution of the Rop RBM Rop protein in a buffer containing 4 M urea and 20 mM Tris HCl (pH 8.0), obtained after dialysis of the fractions collected during chromatography on WorkBeads 40S, was loaded onto a column with 5 ml of WorkBeads 40 DEAE sorbent (Bio Works) pre equilibrated with a buffer containing 4 M urea, 20 mM Tris HCl (pH 8.0). All column manipulations were performed at a flow rate of 1 ml/min. The sorbent with immobilized protein was washed with the same buffer (50 ml) until the UV detec tor signal dropped and stabilized. Elution of the target protein was performed with a 0 1 M NaCl concentration gradient in 4 M urea in the same buffer by five column volumes. Pure Rop RBM Rop protein was contained in the unbound protein fraction. When eluted from the sor bent, impurity proteins were also eluted along with the target protein. The pooled protein fractions (14 ml) of unbound protein were incubated in the elution buffer for a day, after which the protein solution was dialyzed against 1 liter of 20 mM sodium phosphate buffer (pH 5.5) at 4°C with two buffer changes.

Hydrolysis of the Rop RBM Rop protein with trypsin in electrophoresis gel before mass spectrometry. Proteins separated by PAGE were hydrolyzed inside the gel frag ments according to the method proposed by Shevchenko et al. [9] with and without addition of DTT and iodoacetamide (IAA). Tryptic peptides were extract ed from the gel according to the method we published earlier [10] . The obtained extract was dried to dryness using a Savant SPD121P vacuum concentrator (Thermo Scientific, USA) and dissolved in 20 μl of 0.1% formic acid. The samples were desalted on self made columns with a reverse phase membrane (analogue C18); the sam ple was eluted with 90% solution of acetonitrile in water. For further use, 4 μl of a sample in 90% acetonitrile was taken and mixed with 1 μl of a saturated solution of 2.5 dihydroxybenzoic acid in a 30% acetonitrile solution containing 0.5% glacial acetic acid (v/v) on a steel target following by air drying at room temperature.

MALDI mass spectrometry analysis. Analysis of the peptides was carried out with an Ultraflextreme time of flight MALDI mass spectrometer (Bruker Daltonik GmbH, Germany). Reflectron mode was used for detec tion of positive ions at the following voltages: IS1 -20.12 kV, IS2 -17.82 kV; Lens -7.47 kV, Ref1 -21.07 kV, Ref2 -10.80 kV.

Ions were detected in the m/z range 650 5000. Peaks of autolytic fragments of trypsin and keratin were used as internal standards, which were then excluded from the final lists of detected masses.

Fragmentation of individual ions was carried out under conditions of dissociation induced by the collision of ions with argon molecules, in the detection mode of positive ions at the following voltages: IS1 -7.50 kV, IS2 -6.7 kV; Lens -3.50 kV, Ref1 -29.50 kV, Ref2 -14.00 kV; Lift1 -19 kV, Lift2 -2.80 kV. Laser power in the process of recording mass spectra was varied to achieve best fragmentation of the ions under study.

Analysis of mass spectrometry data. Mass spectra were processed using the Flex Analysis 3.4 software (Bruker Daltonik GmbH). Mass spectra were smoothed according to the Savizky -Golay algorithm (width 0.2 m/z, 1 cycle) and baseline was subtracted according to the TopHat algorithm. The following parameters of peak detection were used: peak detection algorithm was SNAP2, signal to noise ratio was 3, maximum number of peaks in the spectrum was 500. Search and identification of the proteins by the "peptide mass fingerprint" method in the database was carried out using the software com plex MASCOT (local version 2.1.03, Matrix Science, Great Britain). The following search parameters were used: accuracy in determining the mass -50 ppm, possi ble post translational modifications -oxidation of methionine, histidine, tryptophan, Glu pyro Glu, Gln → pyro Gln. Proteins with a probability parameter MOWSE score >32 were reliably identified (95%, p < 0.05). Additional criteria for reliability of determina tion of the primary structure of a protein was coincidence of its molecular weight with the value determined experi mentally. Interpretation of mass spectra, in particular of fragmentation, was additionally carried out using the pro grams Biotools (version 3.2) and Proteinscape (ver sion 4.1) (Bruker Daltonik GmbH).

Obtaining the receptor binding domain (RBD) of the surface Spike protein of the SARS CoV 2. Amino acid sequence of the receptor binding domain (RBD) of the surface Spike protein of the SARS CoV 2 (319 541 aa, UniProtKB ID: locus SPIKE_SARS2, accession P0DTC2) was modified at the N terminus with the alka line phosphatase signal peptide SEAP (MLLLLLLL GLRLQLSLGI) and at the C terminus with a glycine serine linker and histidine tag sequence (GSHHHHHH HHHH). Nucleotide sequence of the obtained polypep tide was synthesized by the Evrogen company and cloned into the pCEP plasmid at the XbaI and HindIII restric tion sites, thus obtaining the pCEP RBD plasmid. Then, the CHO S cell culture (Thermo Fisher Scientific) was transiently transfected with the pCEP RBD plasmid using the CHOgro system (Mirus Bio, USA) in accordance with the manufacturer's protocol. The cells were cultured in Erlenmeyer flasks at 125 rpm, 5% CO 2 , 80% humidity, 37°C, after 24 h the temperature was lowered to 32°C and culturing was continued for 10 days. Starting from the 3rd day, Cell boosts 7a (2%), 7b (0.2%) (HyClone, USA) and 0.5% CHO Bioreactor Feed (Sigma, USA) were added once a day. After 10 days, the culture fluid was clarified by centrifugation at 5,000g. The receptor binding domain was purified by metal affinity chromatography on a BIOCHEMISTRY (Moscow) Vol. 86 No. 10 2021 Immunization of laboratory animals. We used female mice of the syngeneic inbred BALB/c line at the age of 5 6 weeks, weighing 18 20 g (n = 35, NF Gamaleya Research Center for Epidemiology and Microbiology, Ministry of Health of Russia). Mice divided into four experimental groups (n = 7) were injected three times with immunogenic compositions containing recombinant proteins, with an interval of two weeks. The injection was performed with a disposable sterile insulin syringe subcu taneously at the withers of the animal. The volume of injection solution was 150 μl. The animals of the control group (n = 7) were injected with physiological saline according to the described scheme. Immune response was investigated two weeks after the last injection. Throughout the experiment, constant monitoring of physiological state of the experimental animals was car ried out. Two weeks after the last injection, laboratory animals of the experimental and control groups were anesthetized by inhalation of isoflurane (Piramal Enterprises, India) and blood samples were collected from the cardiac cavity to determine antibody titer in the blood serum. After collecting all individual blood samples in vacuum tubes, they were left at room temperature for 20 min, then centrifuged for 30 min at 1500g without refrigeration. Supernatant was transferred into sterile 1.5 ml tubes and frozen at -80°C.

Enzyme linked immunosorbent assay. Presence of the specific immunoglobulins of class G (IgG) was deter mined in serum samples of mice after three injection immunization. The proteins used for immunization, the formalin inactivated SARS CoV 2, and the RBD Spike protein of the SARS CoV 2 were adsorbed onto the plates as antigens. Virus preparation was obtained by propagation of SARS CoV 2 in a Vero cell culture (ATCC bank, CCL 81 line) for 4 days. Then the super natant was collected and centrifuged at room temperature at 3500 rpm (1900g) for 10 min. To inactivate the virus, formalin (37% formaldehyde) was added to the super natant at a ratio of 1 : 1000. After incubation of the virus with formalin for 96 h, ultracentrifugation was performed in a JA 30.50 rotor at 28,700 rpm (∼100,000g) for 3 h at 4°C through a 30% sucrose pad. Supernatant was removed, and pellet was resuspended in Dulbecco's phos phate buffered saline (DPBS). Protein concentration was measured with a Qubit fluorometer (Invitrogen, USA) using the Quant iT Protein Assay Kit (Invitrogen) according to the manufacturer's recommendations. For ELISA, a preparation of the formalin inactivated virus with protein concentration of 1 μg/ml was used.

Sorption of antigens diluted in DPBS to a concen tration of 1.0 μg/ml was carried out overnight at 4°C in 96 well Maxisorp plates (Thermo Scientific, Denmark) (100 μl per well). Then the plates were washed twice with a solution of 0.1% Tween 20 (Serva, Germany) in sodium phosphate buffer (PBS) using an ELx50 automatic wash er (BioTek, USA), 500 μl per well. After washing, the plates were incubated with blocking buffer containing PBS and 5% dry milk powder (TF Ditol, Russia) for 2 h at room temperature, then washed again. After that, a series of tenfold dilutions of experimental mice sera were added to the plate. Plates with serum were incubated for 1 h at room temperature, then washed 3 times. Goat anti Mouse IgG (H + L) labeled with horseradish peroxidase (Invitrogen) were used as secondary antibodies at a dilu tion of 1 : 1200, 100 μl per well. After incubation with sec ondary antibodies, the plates were washed 4 times. A solution of tetramethylbenzidine (TMB) (Bioservice, Russia) was added as a chromogenic substrate, 100 μl per well, followed by incubation for 10 min at room tempera ture, then the reaction was stopped by adding 1 N H 2 SO 4 . Optical density at a wavelength of 450 nm was measured with a CLARIOstar microplate reader equipped with LVF monochromators (based on linear variable filters) (BMG Labtech, USA).

Statistical analysis. Statistical analyses were per formed using the Statistica 12.0 software package (Statsoft, USA). Data were presented as mean ± standard deviation (SD) or as geometric mean ± geometric stan dard deviation of the logarithm 2 base of the antibody titer. Distribution normality was tested using the Kolmogorov-Smirnov test. To assess statistical signifi cance of the differences in the data, a two way analysis of variance (one way ANOVA) with Tukey's post hoc analy sis was used. Differences were considered significant at p < 0.05.

Rop Tri HBD, Rop D3 Rop Tri HBD, Rop D2 Rop ALD HBD, and Rop D3 Rop ALD HBD were obtained, immunogenic properties of which were planned to be investigated. The proteins contain the selected regions D2 or D3 of the RBM Spike protein of the SARS CoV 2 that have many amino acid residues in their com position forming contacts with ACE2 and neutralizing antibodies (Fig. 1 ). We will further call these regions anti genic determinants or epitopes D2 and D3. The sequences of the selected determinants overlap: D2 corre sponds to 470 490 aa, and the D3 sequence corresponds to 453 494 aa of the Spike protein of the SARS CoV 2 (UniProtKB ID: locus SPIKE_SARS2, accession P0DTC2) (Fig. 1) . In the D3 sequence the hydrophobic phenylalanine residue at position 464 in the native struc ture of the Spike protein, which has its hydrophobic rad ical facing towards interior of the molecule and not form ing contacts with antibodies, was replaced by a hydrophilic serine residue in order to prevent possible for mation of the aggregates of vaccine proteins with D3 due to hydrophobic interactions. Glutamic acid residue at position 484 in many strains of the SARS CoV 2 virus, in particular in the South African line B.1.351 was replaced by a lysine residue. Within the selected determinants, there are two cysteine residues, at positions 480 and 488, which form a disulfide bond in the native structure of the Spike protein.

Both determinants were chosen in such a way that their N and C terminus were brought close together in the three dimensional structure of the Spike protein (Fig. 2) , and this position could be fixed due to addition al scaffold structure attached to them. The epitope scaf fold in all four proteins is represented by two α helices of the Rop like protein from M. capsulatus contacting with each other (2 34 and 35 66 aa, PDB code: 2JS5_A, RefSeq ID WP_010959602). Between 34 and 35 aa of the Rop like protein, the D2 or D3 sequences were inserted. Thus, in the protein sequences, both determinants are flanked by α helices of the Rop like protein. In addition to the proximity of the ends, the loop like conformation of both determinants should also be maintained by a disulfide bond between the cysteine residues 480 and 488. The presence of an additional disulfide bond allows expecting good correspondence of the native conforma tion of the regions of the selected determinants to the native structure of these regions in the SARS CoV 2 Spike protein.

Domains providing trimerization are attached to the C terminus of the Rop D2/D3 Rop hybrid molecules through the linker sequence, or α helix sequence mediat ing trimerization of the SARS CoV 2 (Tri) Spike protein (958 991 aa, identifier UniProtKB: locus SPIKE_SARS2, accession P0DTC2), or the sequence of aldolase from T. maritima (2 201 aa, PDB code: 1WA3). At the C ter minus of all four proteins a short region of the heparin binding domain (HBD) of the Heparin binding hemag glutinin (HBHA) protein from M. tuberculosis (160 174 aa, UniProtKB/Swiss Prot ID: A1KFU9) is inserted, which allows purification of the obtained proteins on the heparin containing sorbents. Quaternary structure of the obtained proteins was not characterized, but, presumably, they should spontaneously form homotrimers in solution, each with three identical loop shaped structural epitopes in the N terminal part. Schematic diagram of the pre sumed structure of the trimers of the obtained fusion pro teins is shown in Fig. 2 .

Molecular weight of the monomeric proteins -from 18.7 to 38.7 kDa -is already considered sufficient for effective antibody production. Increase in molecular weight during trimerization should further enhance immune response to the hybrid antigens.

To confirm existence of a disulfide bond in the pro teins containing loop like Spike protein fragments with Cys480 and Cys488 and the proteins obtained by synthe sis in E. coli, a protein containing a full length RBM flanked by sequences from the Rop like protein was designed. The receptor binding motif in the native Spike protein forms a loop like structure that includes loop like epitopes D2 and D3 at the top of the hairpin. [7] ). Variable amino acid residues E484 and N501 are in italic. Asterisks mark amino acid residues interacting with ACE2, and hash signs indicate amino acid residues interacting with at least one of 13 neutralizing antibodies with a known three dimensional structure (in accordance with Fig. 2 from Lee et al. [11] ). Interaction criteri on -the distance between residues is not more than 4.5 Å.

BIOCHEMISTRY (Moscow) Vol. 86 No. 10 2021 D2 Rop ALD HBD and Rop D3 Rop ALD HBD were synthesized in a soluble form. Accordingly, isolation schemes for these proteins differed: proteins with a trimerizer from SARS CoV 2 and Rop RBM Rop were isolated under denaturing conditions in the presence of urea, while proteins with aldolase were isolated under non denaturing conditions (Fig. 3) . WorkBeads 40S sor bent was used as the first stage of purification for all pro teins. At the second stage, four proteins containing the heparin binding domain were purified on the heparin sepharose and further used for immunization.

The second stage of Rop RBM Rop protein purifi cation was carried out using WorkBeads 40 DEAE, most of the impurity proteins were strongly bound to the sor bent in the process, and major amount of the target pro tein did not bind to the sorbent and, after passing through the column, came out in a highly purified and sufficient ly concentrated form (Fig. 3f, lane 2) . The yield of pro teins was 4.8 8.0 mg per 1 g of raw biomass, and the degree of purification was 97 98%.

Characteristics of proteins, including experimental data and theoretical values of some parameters obtained using the Internet resource https://web.expasy.org/ protparam/, are presented in Table 1 .

To identify the protein under study, the bands of interest from PAGE were subjected to trypsinolysis by adding and not adding the reducing agent DTT and iodoacetamide (IAA) before the protein proteolysis reaction in the gel. In the presence and absence of DTT and IAA, the S-S bonds in the pro tein should, respectively, be restored (destroyed) or retained. The MALDI mass spectrum of the obtained peptides is shown in Fig. S1 , b and c in the Supplement.

Protein preparation treated with DTT and IAA pro duced mass spectrum (Fig. S1c in the Supplement) that contained several peaks corresponding to tryptic and chy motryptic cysteine containing peptides of the Rop RBM Rop protein, while cysteines in these peptides were present only in the form of S carbamidomethylcysteines. Thus, the peak with m/z 2145.0365 corresponds to the peptide DISTEIYQAGSTPCNGVEGF (77 96 aa), the peak with m/z 2582.0867 corresponds to DIS When comparing mass spectra of the hydrolysates of the Rop RBM Rop samples (Fig. S1 , b and c in the Supplement), it was shown that in the sample analyzed under non denaturing conditions, no peaks correspon ding to peptides containing cysteine residues in the form of S carbamidomethylcysteines, S propionamidocys teines or peptides with free unmodified cysteine residues were detected, while there were peaks confirming the presence of a disulfide bond in the protein under study. Detailed analysis of the peaks corresponding to the cys teine containing peptides identified in the Rop RBM Rop DTT IAA protein with a disulfide bond formed between the cysteines is presented in Table S1 in the Supplement.

The peaks with m/z 2631.1467; 3791.486; 2561.1583 and 1645.6688 correspond to two possible structures of peptides, however, they have the same empirical formula and differ only in the position at which the cleavage of the polypeptide chain by trypsin took place (italicized in Table S1 in the Supplement). The structure of ions with m/z 2561.044; 2865.261 and 3791.486 was additionally confirmed by the tandem mass spectrometry. The colli sion induced dissociation (CID) mass spectra (Fig. S2 in the Supplement) contain peaks corresponding to the a , y , and b series of fragments of the corresponding parent ions, the structures of which were assumed based on the analysis of the mass spectrum of the tryptic hydrolysate ( Fig. S1c ; Table S1 in the Supplement) -this fact addi tionally confirms correctness of the determined structure of these ions.

Thus, mass spectrometry showed the presence of S-S bond between the cysteines 90 and 98 (480 and 488) The rest of the proteins were not analyzed with mass spectrometry. Formation of the disulfide bond in the iso lated proteins was detected from the difference in elec trophoretic mobility of the bands corresponding to the reduced (heated at 95°C in the presence of the reducing agent DTT) and unreduced forms of the protein. In the Rop RBM Rop protein, for which the presence of disul fide bond was shown by mass spectrometry, the reduced form has lower mobility in the gel (Fig. 3) . Similar behav ior is typical for all four proteins with determinants D2 and D3 (Fig. 3) . This confirms the presence of disulfide bond in the isolated proteins.

Antibody formation after immunization. Immuno genic compositions based on four proteins were used to immunize BALB/c inbred mice. Two weeks after the last of three injections administered with 2 week interval, presence of the specific immunoglobulins of class G (IgG) in the serum samples of mice was determined. The antigens used were the same proteins that were used for immunization, the SARS CoV 2 inactivated by formalin, and the RBD of the Spike protein of the SARS CoV 2. The results of immunization are presented in Table 2 .

As can be seen from the data presented in Table 2 , all four proteins induced formation of IgG antibodies in mice at a sufficiently high titer interacting both with the antigen itself used for immunization, with the inactivated virus, and with RBD. The most immunogenic proteins are Rop D2 Rop ALD HBD and Rop D3 Rop ALD HBD. The least immunogenic is the Rop D3 Rop Tri HBD protein. The most pronounced response to RBD was observed in the case of the Rop D3 Rop ALD HBD protein. The most pronounced response to the inactivat ed SARS CoV 2 was observed in the group of animals immunized with the Rop D2 ALD HBD protein. The described comparisons can be considered as observed trends, since the sample size used in the experiment (seven animals per group) is insufficient to provide statis tical significance (two way ANOVA using the Tukey post hoc, p < 0.05).

High titers of antibodies interacting with RBD obtained in a eukaryotic producer, as well as with inacti vated SARS CoV 2, indicate that the recombinant pro teins obtained in this work, containing short RBM frag ments corresponding to conformational epitopes D2 and D3, can effectively induce production of the specific anti bodies. One of the important circumstances, which prob ably largely determines efficiency of antibody production, is that there are no glycosylation sites within the selected determinants in the Spike protein, therefore, the virus surface regions and RBD in the region of the D2 and D3 determinants are not modified by sugar residues similar to the epitopes D2 and D3 in the proteins obtained in our work and synthesized in bacterial cells. In our case, attachment of the N and C terminus of the D2 and D3 determinants to the α helices of the Rop like scaffold protein, apparently, provides high conformational simi larity between the D2 and D3 loops in the recombinant proteins and in the native Spike protein. This is also evi denced by the formation of characteristic disulfide bond, directly demonstrated for the Rop RBM Rop protein using mass spectrometry and indirectly for all four pro teins used for immunization (from the reduced mobility of the reduced form during PAGE). In the future, it is planned to obtain other recombinant proteins based on the platform developed in this work that include promis ing viral epitopes that are not necessarily loop shaped. If these epitopes have any other stable conformation, for example, α helical, or represent β sheet regions, flexible glycine containing linkers will be used to attach them to the Rop like scaffold protein. Conformation of the epi topes can be additionally stabilized by replacing amino acid residues that do not interact with antibodies and the receptor with cysteine residues, which will ensure prox imity of their protein chains via formation of disulfide bonds. This approach was implemented in the work by Zuniga et al. [12] during development of the epitope vac cine based on short protein fragments of the respiratory syncytial virus (RSV) conjugated with synthetic nanopar ticles.

The presence of trimerization domains in proteins probably leads to additional enhancement of the immune response due to increased size of the antigen. The maxi mum effect is observed in the case of proteins with aldolase (Fig. 2) . The ability of aldolases to spontaneous ly multimerize is often used to obtain candidate vaccines based on protein nanoparticles, in particular, vaccines based on the RBD of coronaviruses [13 15] . Aldolase used in our work is a rather large protein compared to viral determinants, so it can be assumed that among the antibodies produced, a significant part of antibodies will be produced specifically against aldolase and other addi tional domains of the recombinant proteins. Nevertheless, in numerous works on the creation of vac cines based on the viral and other proteins capable of self assembly that form huge protein complexes (for example, consisting of 24 or 60 subunits), the formation of cross specific or autoreactive antibodies to the protein compo nents of the carrier has not been reported [16] . However, in this work, in addition to aldolase, we also used another trimerizer -α helix from the Spike protein of the SARS CoV 2, which is much smaller in size and, therefore, should "pull" the "antibody response" to itself to a lesser extent, besides, it originates from the same virus as the target antigens. A similar trimerizer (27 aa foldon domain BIOCHEMISTRY (Moscow) Vol. 86 No. 10 2021 of fibritin from bacteriophage T4) has been used for a long time to obtain candidate vaccines based on the viral proteins, in particular, it is used in the previously devel oped vaccines against SARS CoV and MERS [17, 18] . These vaccines and other protein vaccines against coron aviruses [13, 15] contain large fragments or the whole Spike protein of coronaviruses synthesized in eukaryotic expression systems as an antigenic component. All of them have high immunogenicity and, to a greater or less er extent, cause production of the virus neutralizing anti bodies. The aim of this work was to obtain short determi nants of the SARS CoV 2 Spike protein (epitopes) with a native conformation in E. coli, to study their immuno genicity and ability of antibodies formed in response to them to interact with RBD protein and inactivated virus. Successful implementation of this stage of the study allows us to proceed to the study of the virus neutraliza tion effect of the obtained antibodies, expanding the list of studied determinants, and to the subsequent stages of developing of epitope vaccine.

It should be noted that within both selected determi nants in the RBD sequence there is a glutamic acid residue E484, which, when replaced with lysine, provides lower binding efficiency with monoclonal antibodies and sera of patients who have been infected and vaccinat ed [19 21 ]. This mutation is present in new variants of the SARS CoV 2, derived from the B.1.1.28 lineage, first described in Brazil and Japan (P.2 and P.1), as well as in the strains of the B.1.351 line, also known as 501Y.V2, first identified in South Africa, and now widespread [22] . Based on the platform developed in the article, it is tech nically easy to obtain variants of immunogenic recombi nant proteins containing the E484K substitution. Introduction of both variants of proteins into the vaccine composition should ensure production of the antibodies that bind to both the original and mutant variants of the virus.

The approach closest to the one proposed in our work was implemented in the study by Lu et al. [7] , with in which the surface B cell epitopes of the Spike protein were predicted and synthesized, and vaccines based on the virus like particles (VLPs) of the hepatitis B virus core protein (HBc) were created using the SpyCatcher/SpyTag system [7] . Immunogenicity of the epitopes was tested using sera from mice 10 days after three injection immunization with two week intervals. For epitope S455 469, which is part of the D3 sequence, and epitope S475 499, which is part of both D2 and D3 (Fig. 1) , high immunogenicity was shown in the ELISA experiments using peptides as antigens (antibody titer in sera of mice >10 4 ).

Lu et al. [7] used short linear synthetic peptides, their density on the virus like particles and size of the particles themselves are probably higher in comparison with the trimeric hybrid proteins obtained in our work. Nevertheless, when using our approach, the antibody titer in the sera of mice also exceeds 10 4 . In our study, activity of the mouse sera against RBM and inactivated virus was also shown, which indicated native conformation of the loop shaped epitopes obtained by us. In the study by Lu et al. [7] neutralizing activity of the generated anti bodies against pseudoviruses for epitopes S455 469 and S475 499 of variants D614 and G614 was also shown. This suggests that immunization with proteins with epi topes D2 and D3 will also lead to the formation of virus neutralizing antibodies against both variants of viruses.

Thus, on the basis of fusion proteins, including the Rop like protein from M. capsulatus and trimerization domains, aldolase from T. maritima or α helix of the Spike protein of SARS CoV 2, a platform has been cre ated for obtaining immunogenic constructs containing conformational epitopes with continuous amino acid sequence, in particular, the epitopes of the SARS CoV 2 proteins, which can be used to create new variants of epi tope vaccines for prevention of COVID 19. Future work would involve expansion of the spectrum of the investi gated determinants and characterization of their ability to induce formation of the neutralizing antibodies. Production of the proteins via microbiological synthesis is an inexpensive alternative to the production of proteins by synthesis in eukaryotic cells. The choice of epitopes, significant part of which are exposed on the protein sur face, including amino acid residues involved in interac tion with neutralizing antibodies and not containing gly cosylation sites, seems to be the optimal strategy.

Funding. This work was supported by the Russian Foundation for Basic Research (grant no. 20 04 60373\20 "Development of approaches for design of a new type of preventive vaccine against COVID 19 based on the use of recombinant SARS CoV 2 antigens as a part of chimeric protein nanoparticles").

Ethics declarations. The authors declare no conflict of interest in financial or any other sphere. All applicable international, national and/or institutional guidelines for the care and use of animals have been followed.

Supplementary information. The online version con tains supplementary material available at https://doi.org/ 10.1134/S0006297921100096.

Antibodies, viruses and vaccines

Heads, stalks and everything else: how can antibodies erad icate influenza as a human disease?

Recent progress in broadly neutralizing antibodies to HIV

Dengue virus sero cross reactivity drives antibody dependent enhancement of infection with zika virus

Structural basis of a shared antibody response to SARS CoV 2

Epitope based vaccine design yields fusion peptide directed antibodies that neutralize diverse strains of HIV 1

The immunodominant and neutralization linear epitopes for SARS CoV 2

Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold

In gel digestion for mass spectrometric characterization of proteins and proteomes

Recombinant human erythropoietin with additional processable protein domains: purification of protein syn thesized in Escherichia coli heterologous expression system

A novel neutralizing antibody targeting receptor binding domain of SARS CoV 2

An epitope specific chemically defined nanoparticle vaccine for respiratory syncytial virus, Vaccines

Mosaic nanoparticles elicit cross reactive immune responses to zoonotic coronaviruses in mice

Rapid Development of SARS CoV 2 spike protein receptor binding domain self assembled nanopar ticle vaccine candidates

A COVID 19 vaccine candi date using SpyCatcher multimerization of the SARS CoV 2 spike protein receptor binding domain induces potent neutralising antibody responses

The versatile manipulations of self assembled pro teins in vaccine design

Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates

A recombinant receptor binding domain of MERS CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS CoV infection

Antibody cocktail to SARS CoV 2 spike protein prevents rapid mutational escape seen with individual anti bodies

Complete mapping of mutations to the SARS CoV 2 spike receptor binding domain that escape antibody recognition

Comprehensive mapping of mutations in the SARS CoV 2 receptor binding domain that affect recognition by polyclonal human plasma anti bodies

Sixteen novel lineages of SARS CoV 2 in South Africa